G3 pharmaceuticals Inc. is a development-stage biopharmaceutical company located in Lexington, Massachusetts. We form partnerships with those scientists and clinicians around the world who have advanced the understanding of galectin-3 over the past decade. We develop proprietary carbohydrate inhibitors for pharmaceutical development by studying research compounds known to bind and inhibit galectin-3. In parallel we continue to investigate the role of galectin-3 in heart, kidney and lung disease so that when our inhibitors are ready for clinical testing we understand which patients are most likely to benefit.